Form 8-K

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)        April 1, 2003    

 


 

Targeted Genetics Corporation

(Exact name of registrant as specified in charter)

 


 

Washington

 

0-23930

 

91-1549568

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

1100 Olive Way, Suite 100, Seattle, Washington

 

98101

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code         (206) 623-7612    

 

 

Not Applicable

(Former name or former address, if changed since last report)

 



 

Item 5. Other Events.

 

On April 1, 2003, Targeted Genetics Corporation announced that it had signed a contract manufacturing agreement with GenVec, Inc. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.

 

Item 7. Exhibits.

 

  (a)   Financial statements of business acquired.

 

Not applicable.

 

  (b)   Pro forma financial information.

 

Not applicable.

 

  (c)   Exhibits.

 

Exhibit No.


  

Description


99.1

  

Press Release dated April 1, 2003


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

TARGETED GENETICS CORPORATION

 

Date: April 2, 2003

     

By:

 

/s/    TODD E. SIMPSON        


               

Todd E. Simpson

Vice President, Finance and Administration and

Chief Financial Officer, Secretary and Treasurer

(Principal Financial and Accounting Officer)


EXHIBIT INDEX

 

Exhibit No.


  

Description


99.1

  

Press Release dated April 1, 2003